Wed, Sep 17, 2014, 4:10 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Advanced Medical Isotope Corporation Message Board

  • itrader250 itrader250 Jul 28, 2014 10:09 PM Flag

    Intrader is Long & Strong ADMD, and I've loaded up on shares and

    believe 100% in RadioGel as the Future of Brachytherapy, and so does Battelle, why else would they buy 11% of AMIC ?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • SB, we are laughing at you, your not very good at bashing a share price down, I've loaded more because of you. Thanks.

    • Battelle didn't buy anything pumper. They took shares because deadbeat ADMD couldn't pay their debts. Nobody else wanted worthless radiogel. It's a scam.

    • Short of announcing FDA approval for AMIC’s brachytherapy products, the PR is probably the most exciting news AMIC could reasonably expect to receive for its future prospects. Battelle Memorial Institute – the extremely highly regarded scientific and medical research institution with 22,000 employees, global operations and last year revenues exceeding $6.2 billion, has acquired about a 10% interest in AMIC.

      Name another small cap that can say that ???

      You can't, lmao

      • 1 Reply to itrader250
      • By taking this interest in AMIC, Battelle:

        1. Marries a significant equity interest to its patent license, re-emphasizing Battelle’s collaboration with AMIC to support the brachytherapy products as a break-through in treating cancer;

        2. Sends an unmistakable message to the FDA, regulators worldwide and potential customers that AMIC is not alone, but, rather, has the support of what is probably the world’s leading non-profit scientific and medical research institute. I feel that is the most powerful endorsement AMIC could ever hope to obtain; and

0.0047-0.0008(-14.55%)3:54 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.